Here at The Motley Fool, I've long cautioned investors to keep a close eye on inventory levels. It's a part of my standard diligence when searching for the market's best stocks. I think a quarterly checkup can help you spot potential problems. For many companies, products that sit on the shelves too long can become big trouble. Stale inventory may be sold for lower prices, hurting profitability. In extreme cases, it may be written off completely and sent to the shredder.
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Baxter International (NYSE: BAX ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Baxter International doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue increased 1.8%, and inventory increased 8.3%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue grew 1.8%, and inventory increased 8.3%. Over the sequential quarterly period, the trend looks worrisome. Revenue dropped 8.1%, and inventory grew 5.7%.
Top 5 Forestry Stocks To Own Right Now: Warner Chilcott plc(WCRX)
Warner Chilcott Public Limited Company, a specialty pharmaceutical company, together with its subsidiaries, engages in the development, manufacture, and promotion of branded pharmaceutical products focusing on the women?s healthcare, gastroenterology, dermatology, and urology markets in North America and western Europe. Its principal products include ACTONEL for the prevention and treatment of postmenopausal osteoporosis; ATELVIA for the treatment of postmenopausal osteoporosis; LOESTRIN 24 FE and LO LOESTRIN FE, which are oral contraceptives for the prevention of pregnancy; ESTRACE cream, a vaginal cream for the treatment of vaginal and vulvar atrophy; ASACOL for the treatment of ulcerative colitis for orally administered 5-aminosalicylic acid products and maintenance of remission; ASACOL HD for the treatment of moderately active ulcerative colitis; DORYX, a tetracycline-class oral antibiotic for the treatment of severe acne; and ENABLEX for the treatment of overactive b ladder. The company markets its products and services through wholesale pharmaceutical distributors, and retail drug store chains. It has a strategic collaboration agreement with Sanofi-Aventis U.S. LLC. Warner Chilcott Public Limited Company was founded in 1968 and is headquartered in Dublin, Ireland.
Advisors' Opinion:- [By Dan Caplinger]
Tomorrow, Warner Chilcott (NASDAQ: WCRX ) will release its latest quarterly results. The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you'll be less likely to make an uninformed kneejerk reaction to news that turns out to be exactly the wrong move.
5 Best Heal Care Stocks To Buy For 2014: Sucampo Pharmaceuticals Inc (SCMP)
Sucampo Pharmaceuticals, Inc., incorporated on December 9, 2008, is a global biopharmaceutical company focused on research, discovery, development and commercialization of drugs based on ion channel activators known as prostones. The Company�� prostone-based compounds target the ClC-2 and big potassium (BK), ion channels. It is focused on developing prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other therapeutic applications of its drug technology. The Company�� products include AMITIZA (lubiprostone) and RESCULA (unoprostone isopropyl).
AMITIZA
The Company�� AMITIZA is being marketed in the United States for three gastrointestinal indications under a license agreement, or the Takeda Agreement, with Takeda Pharmaceutical Company Limited, or Takeda. The three gastrointestinal indications include chronic idiopathic constipation (CIC), in adults, irritable bowel syndrome with constipation (IBS-C), in adult women, and opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. AMITIZA for OIC received approval from the United States Food and Drug Administration (FDA), in April 2013. In Japan, AMITIZA is marketed under a license, commercialization and supply agreement, or the Abbott Agreement, with Abbott Japan Co. Ltd. (Abbott), for the gastrointestinal indication of chronic constipation (CC), excluding constipation caused by organic diseases. In Switzerland, the Company is marketing AMITIZA.
RESCULA
The Company holds license agreements for RESCULA in the United States and Canada and the rest of the world, with the exception of Japan, Korea, Taiwan and the People�� Republic of China. The Company is commercializing RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of intraocular pressure (IOP), in patients with open-angle glaucoma or ocular hypertension in the United States. RESCULA may be used as an agent or concomit! antly with other topical ophthalmic drug products to lower intraocular pressure. RESCULA is a BK channel activator and has a different mechanism of action than other IOP lowering agents on the market.
Advisors' Opinion:- [By James Brumley]
Still, for the nimble who know when to get out, OREX is one of the few cheap stocks worth a closer look.
Sucampo Pharmaceuticals (SCMP)Finally, though the price of $7.60 clearly qualifies it as one pf the cheapest of the cheap stocks out there in the pharmaceutical world, that’s not the reason Sucampo Pharmaceuticals (SCMP) may be worth a look here. It’s the 30% slide we’ve seen SCMP stock suffer since peaking in mid-January. It’s not a pullback that’s bound to go unchallenged by the bulls.
- [By Roberto Pedone]
Another under-$10 stock that's starting to trend within range of triggering a major breakout trade is Sucampo Pharmaceuticals (SCMP), which is engaged in the discovery, development and commercialization of proprietary drugs based on prostones, and other novel drug technologies. This stock is off to a decent start in 2013, with shares up by 26%.
If you take a look at the chart for Sucampo Pharmaceuticals, you'll notice that this stock has been downtrending badly for the last four months, with shares dumping hard from its high of $10.48 to its recent low of $5.40 a share. During that downtrend, shares of SCMP have been consistently making lower highs and lower lows, which is bearish technical price action. That said, the downside volatility for SCMP looks to be over in the short-term since the stock has started to reverse its downtrend and enter an uptrend. That reverse is quickly pushing shares of SCMP within range of triggering a major breakout trade above a key downtrend line.
Traders should now look for long-biased trades in SCMP if it manages to break out above some near-term overhead resistance levels at $6.33 to $6.66 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 115,383 shares. If that breakout triggers soon, then SCMP will set up to re-test or possibly take out its next major overhead resistance levels at $7.09 to $7.67 a share. Any high-volume move above those levels will then give SCMP a chance to tag $8 to $9 a share.
Traders can look to buy SCMP off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $5.58 to $5.40 a share. One can also buy SCMP off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
5 Best Heal Care Stocks To Buy For 2014: DCT Industrial Trust Inc (DCF)
DCT Industrial Trust Inc. (DCT) is an industrial real estate company that owns, operates and develops bulk distribution and light industrial properties in distribution markets in the United States and Mexico. The Company is structured as an umbrella partnership real estate investment trust (REIT), under which substantially all of its business is, and will be, conducted through a majority-owned and controlled subsidiary, DCT Industrial Operating Partnership LP (the operating partnership), a Delaware limited partnership, for which DCT Industrial Trust Inc. is the sole general partner. The Company owns properties through its operating partnership and its subsidiaries. As of December 31, 2011, DCT owned approximately 90% of the outstanding equity interests in its operating partnership. In March 2012, DCT acquired a 32.6 acre land parcel in Romeoville, within the southern I-55 industrial submarket of Chicago. In May 2012, the Company acquired two Class A industrial buildings totaling 98,000 square feet in Houston, known as DCT Claymoore Center. Located in the Northwest submarket of Houston, DCT Claymoore Center encompasses a bulk and light industrial facility and is 95.8%-occupied. In August 2013, the Company announced that it has acquired a three building portfolio totaling 308,000 square feet in the Tempe/Airport submarket of Phoenix. In September 2013, Dct Industrial Trust Inc announced the acquisition of 45 acres in the heart of the Inland Empire West submarket of Southern California. In October 2013, DCT Industrial Trust Inc acquired DCT Fox River Business Center, a six-building industrial portfolio in Elgin. In October 2013, DCT Industrial Trust Inc sold its entire portfolio of Mexico assets to an investment trust of Macquarie Mexican REIT.
During the year ended December 31, 2011, the Company acquired 24 buildings comprising 2.8 million square feet and controlling ownership interests in three buildings totaling 0.4 million square feet. In 2011, the Company sold 16 operating properties to! taling approximately 2.7 million square feet to third-parties. As of December 31, 2011, the Company�� consolidated operating properties had leases with approximately 900 customers with no single customer accounting for more than 1.7% of the total annualized base rents of its properties. As of December 31, 2011, the Company owned interests in, managed or had under development approximately 75.5 million square feet of properties leased to approximately 900 customers, including 58.1 million square feet comprising 408 consolidated properties owned in its operating portfolio, which were 90.6% occupied; 0.2 million square feet comprising one consolidated property under redevelopment, and 17.2 million square feet comprising 52 unconsolidated properties, which were 86.3% occupied and one managed-only property operated on behalf of five institutional capital management partners. As of December 31, 2011, its total consolidated portfolio consisted of 409 properties with an average size of 142,000 square feet and an average age of 20.2 years.
Advisors' Opinion:- [By GuruFocus]
Free cash flow is a favorite parameter of value investors. It seems to make sense, because the value of a company is determined by how much cash it can generate over time. Value investors have developed discounted cash flow (DCF) models to estimate the value of companies.
- [By Canadian Value]
As many of our clients know, Jensen focuses primarily on the discounted cash flow (DCF) method to value equities. Our long held belief is that the intrinsic value of a business is the present value of the cash flows the company is expected to pay its shareholders in the future. The remainder of this paper explores some of the advantages and disadvantages of using either DCF or multiples and outlines why we believe DCF is the more fundamentally sound way to value equities.
- [By David Kerr]
Let�� take a look at using a version of the Discounted Cash Flow method (DCF) to valuate the share price. I will use the most recent Earnings Per Share of 2.32, an 18.9% growth rate over the next 10 years (which is the average EPS growth rate of the past 10 years), a Terminal Growth Rate of 2% (average inflation rate for 2013 so far), with 10 years of Terminal Growth at a Discount Rate of 12% to be safe. That leaves us with a Fair Value of $58.85 and a 42% Margin of Safety. That�� a healthy margin.
- [By Robert Rapier]
The partnership has generated $7.6 billion of distributable cash flow (DCF) over the past nine years, paying out just short of three quarters of that total and reinvesting the rest. The long-term distribution coverage checks in at a prudent 134%.
5 Best Heal Care Stocks To Buy For 2014: Opt-Sciences Corp (OPST)
Opt-Sciences Corporation, incorporated on November 1956, conducts its business through its wholly owned subsidiary, O and S Research, Inc. The Company deposits anti-glare and/or transparent conductive optical coatings on glass used primarily to cover instrument panels in aircraft cockpits. It also provides full glass cutting, grinding and painting operations, which augment its optical coating capabilities. Its products are designed to enable pilots to read aircraft instruments in direct sunlight or at night or in covert situations using appropriate night vision filters or to protect the instruments from electromagnetic interference. The Company�� business is dependent on a robust commercial, business, and regional aircraft market and to a lesser degree the military aircraft market. It generally has a four to twelve week delivery cycle depending on product complexity, available plant capacity and required lead time for specialty raw materials, such as polarizers or filter glass.
The Company�� offers incorporate an optical coating of some type. Its primary coatings are for aircraft cockpit display applications and consist of its anti-reflection coating used for glare reduction and its transparent conductive coating used for electromagnetic interference shielding. In addition, it also offers a full range of other specialty instrument glass, including night vision filter glass, circular polarizers, touchpads, glass sandwiches for liquid crystal displays (LCDs) as well as other custom designed specialty glass components and assemblies. It uses its technology to apply a micro thin optical non-glare and/or conductive coating to the glass. Both processes utilize the deposit of a thin film of metal or metal oxide on the surface of the glass. The process takes place in a heated vacuum chamber. It heats the deposited material to over 1800 degrees Centigrade causing it to evaporate.
The Company competes with JDSU, Mod A Can, Dontech, Schott Glass and Hoya Optics
Advisors' Opinion:- [By Geoff Gannon] ng>Micropac
Micropac is 76% owned by Heinz-Werner Hempel. He�� a German businessman. You can see the German company he founded here. He�� had control of Micropac for a long-time. I don�� have an exact number in front of me. But I would guess it�� been something like 25 years.
ADDvantage
ADDvantage Technologies is controlled by the Chymiak brothers. See the company�� April 4 press release explaining their decision to turn over the CEO position to an outsider. Regardless, the Chymiaks still control 47% of the company. Ken Chymiak is now chairman. And David Chymiak is still a director and now the company�� chief technology officer. Clearly, it�� still their company.
By the way, the name ADDvantage Technologies has nothing to do with the Chymiaks. Today�� AEY really traces its roots to a private company called Tulsat. The Chymiak brothers acquired that company about 27 years ago. So, effectively, when you buy shares of AEY you are buying into a 27-year-old family-controlled company.
That�� pretty typical in the world of net-nets.
Solitron
Solitron Devices is 29% owned by Shevach Saraf. He has been the CEO for 20 years. The post-bankruptcy Solitron has never known another CEO. Before the bankruptcy, Solitron was a much bigger, much different company. So even though we are not talking about the founder here ��and even though 70% of the company�� shares are not held by the CEO ��we��e still talking about a company where one person has a lot of control. Solitron only has three directors. Saraf is the chairman, CEO, president, CFO and treasurer. Neither of the other two directors joined the board within the last 15 years. So, we aren�� talking about a lot of tumult at the top.
In fact, profitable net-nets seem to be especially common candidates for abandoning the responsibilities of a public company without actually getting taken private.
OPT-Sciences
This company is controlled by Arthu
No comments:
Post a Comment